Cargo Therapeutics, Inc.: CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and ...
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
SAN CARLOS, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell ...
infectiousdiseaseadvisor.com22h
2024 Novel Drug and Biological Product Approvals
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Le Lézard1d
Vector Solutions Expands Efforts for Firefighter Cancer Awareness Month 2025
Vector Solutions, the leading provider of technology solutions to help train, prepare, and retain public safety professionals, is amplifying its commitment to firefighter health and safety with a ...
Nature1d
Why the last cases of sleeping sickness will be the hardest to eliminate
Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...
The American Journal of Managed Care6d
Gene Therapy Demonstrates High Efficacy in Severe β-Thalassemia
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...